Find trending articles through Social News Discovery®! Providing a collaboration of news through social media technologies.
Follow your friends and create your own Online Social Newspaper! Invite your friends to follow you from Facebook. Filter the news articles you see by section, clipper, or mood. Rate each article and comment on all news clips!
Receive site and email notifications about comments and news clips that you are collaborating on!
Get the latest news on the Everyone page, the viral and trending news clips will always be at the top! See the trending news and articles!
"Drugmaker Gilead Sciences, Inc. (NASDAQ:GILD) is lower ahead of Sunday's second U.S. presidential debate between Hillary Clinton and Donald Trump, as prescription drug costs have been a hot topic -- but call buyers are betting on a quick rebound", www.schaeffersresearch.com
"Providing HIV medication to both members of a couple may substantially reduce the risk of transmission within that couple, according to a study in PLOS Medicine. Jared Baeten of the University of Washington and colleagues conducted a prospective", www.sciencecodex.com
"In an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).", formularyjournal.modernmedicine.com
"Merck & Co. was sitting pretty earlier this year after winning a legal dispute over sofosbuvir, the active ingredient in Gilead's multibillion-dollar babies Sovaldi and Harvoni. But all of that turned around when a judge threw out the victory and snatched back the $200 million Merck had been awarded. Now, to add insult to injury, Merck has been handed a $200 million bill for Gilead’s legal fees.", www.fiercepharma.com
"Healio.com/Hepatology compiled a list of the top 10 news reports on hepatology posted from June 1 to June 30. Healio.com/Hepatology and HCV Next readers were interested in the recent FDA approval of Epclusa for all hepatitis C virus genotypes, obesity and type 2 diabetes increasing cirrhosis burden more than alcohol, and much more. ", www.healio.com
"The FDA has given the green light to Epclusa (Gilead Sciences) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection with or without cirrhosis. For patients with decompensated (moderate-to-severe) cirrhosis, Epclusa is approved for use in combination with ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.", www.ptcommunity.com
"Merck & Co. won’t collect the $200 million it won in a hepatitis C patent fight against Gilead Sciences after all. And according to a federal judge, that’s Merck's own fault--and crucially, the fault of one of its expert witnesses.", www.fiercepharma.com
Please enjoy the site during our beta phase and provide us with feedback on suggestions and issue details. Please remember that we are still in beta and there will be issues and site changes during this time.
Newsclip® the leading Online Social Newspaper, find trending articles through Social News Discovery®!
You can reopen the "Getting Started Tutorial" dialog from within the About menu in the top right corner.